Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T26203
|
||||
Former ID |
TTDI01933
|
||||
Target Name |
ICAM-1
|
||||
Gene Name |
ICAM1
|
||||
Synonyms |
CD54; Intercellular adhesion molecule 1; Major group rhinovirus receptor; ICAM1
|
||||
Target Type |
Clinical Trial
|
||||
Disease | Allergic conjunctivitis [ICD9: 204.0, 372.0, 372.14, 995.3; ICD10: C91.0, H10, H10.45, T78.4] | ||||
Hormone refractory prostate cancer [ICD9: 140-229, 185; ICD10: C61] | |||||
Inflammatory disease [ICD9: 140-229, 147, 173, 573.3, 710-719; ICD10: C11, C44, K75.9, M00-M25] | |||||
Inflammatory bowel disease [ICD9: 555, 556; ICD10: K50, K51] | |||||
Multiple myeloma [ICD9: 203; ICD10: C90] | |||||
Psoriasis [ICD9: 696; ICD10: L40] | |||||
Unspecified [ICD code not available] | |||||
Function |
ICAM proteins are ligands for the leukocyte adhesion protein LFA-1 (integrin alpha-L/beta-2). During leukocyte trans- endothelial migration, ICAM1 engagement promotes the assembly of endothelial apical cups through ARHGEF26/SGEF and RHOG activation.In case of rhinovirus infection acts as a cellular receptor for the virus.
|
||||
BioChemical Class |
Immunoglobulin
|
||||
UniProt ID | |||||
Sequence |
MAPSSPRPALPALLVLLGALFPGPGNAQTSVSPSKVILPRGGSVLVTCSTSCDQPKLLGI
ETPLPKKELLLPGNNRKVYELSNVQEDSQPMCYSNCPDGQSTAKTFLTVYWTPERVELAP LPSWQPVGKNLTLRCQVEGGAPRANLTVVLLRGEKELKREPAVGEPAEVTTTVLVRRDHH GANFSCRTELDLRPQGLELFENTSAPYQLQTFVLPATPPQLVSPRVLEVDTQGTVVCSLD GLFPVSEAQVHLALGDQRLNPTVTYGNDSFSAKASVSVTAEDEGTQRLTCAVILGNQSQE TLQTVTIYSFPAPNVILTKPEVSEGTEVTVKCEAHPRAKVTLNGVPAQPLGPRAQLLLKA TPEDNGRSFSCSATLEVAGQLIHKNQTRELRVLYGPRLDERDCPGNWTWPENSQQTPMCQ AWGNPLPELKCLKDGTFPLPIGESVTVTRDLEGTYLCRARSTQGEVTRKVTVNVLSPRYE IVIITVVAAAVIMGTAGLSTYLYNRQRKIKKYRLQQAQKGTPMKPNTQATPP |
||||
Drugs and Mode of Action | |||||
Drug(s) | SAR-1118 | Drug Info | Phase 3 | Allergic conjunctivitis | [523596], [542538] |
APC-8015F | Drug Info | Phase 2 | Hormone refractory prostate cancer | [522591] | |
BI-505 | Drug Info | Phase 1 | Multiple myeloma | [532319] | |
A-252444.0 | Drug Info | Terminated | Inflammatory disease | [547055] | |
GI-270384X | Drug Info | Terminated | Inflammatory bowel disease | [529903] | |
MOR-102 | Drug Info | Terminated | Psoriasis | [547549] | |
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
Pathways | |||||
KEGG Pathway | NF-kappa B signaling pathway | ||||
Cell adhesion molecules (CAMs) | |||||
Natural killer cell mediated cytotoxicity | |||||
TNF signaling pathway | |||||
Leukocyte transendothelial migration | |||||
African trypanosomiasis | |||||
Malaria | |||||
Staphylococcus aureus infection | |||||
Influenza A | |||||
HTLV-I infection | |||||
Epstein-Barr virus infection | |||||
Rheumatoid arthritis | |||||
Viral myocarditis | |||||
NetPath Pathway | IL5 Signaling Pathway | ||||
IL1 Signaling Pathway | |||||
TSH Signaling Pathway | |||||
IL6 Signaling Pathway | |||||
IL2 Signaling Pathway | |||||
ID Signaling Pathway | |||||
TWEAK Signaling Pathway | |||||
RANKL Signaling Pathway | |||||
TNFalpha Signaling Pathway | |||||
Pathway Interaction Database | Thromboxane A2 receptor signaling | ||||
Glucocorticoid receptor regulatory network | |||||
amb2 Integrin signaling | |||||
Beta2 integrin cell surface interactions | |||||
Reactome | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | ||||
Integrin cell surface interactions | |||||
Interferon gamma signaling | |||||
WikiPathways | Type II interferon signaling (IFNG) | ||||
IL1 and megakaryotyces in obesity | |||||
Human Complement System | |||||
Spinal Cord Injury | |||||
Interleukin-11 Signaling Pathway | |||||
RANKL/RANK Signaling Pathway | |||||
Integrin cell surface interactions | |||||
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||||
Folate Metabolism | |||||
Vitamin B12 Metabolism | |||||
Selenium Micronutrient Network | |||||
References | |||||
Ref 522591 | ClinicalTrials.gov (NCT00849290) Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442). U.S. National Institutes of Health. | ||||
Ref 523596 | ClinicalTrials.gov (NCT01421498) Safety and Efficacy Study of SAR 1118 to Treat Dry Eye. U.S. National Institutes of Health. | ||||
Ref 529903 | Inhibition of endothelial cell adhesion molecule expression improves colonic hyperalgaesia. Neurogastroenterol Motil. 2009 Feb;21(2):189-96. | ||||
Ref 532319 | A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo. Cancer Cell. 2013 Apr 15;23(4):502-15. | ||||
Ref 542538 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7533). | ||||
Ref 527755 | Efficacy of the fully human monoclonal antibody MOR102 (#5) against intercellular adhesion molecule 1 in the psoriasis-severe combined immunodeficient mouse model. Br J Dermatol. 2005 Oct;153(4):758-66. | ||||
Ref 529903 | Inhibition of endothelial cell adhesion molecule expression improves colonic hyperalgaesia. Neurogastroenterol Motil. 2009 Feb;21(2):189-96. | ||||
Ref 532319 | A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo. Cancer Cell. 2013 Apr 15;23(4):502-15. | ||||
Ref 532815 | Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye. ACS Med Chem Lett. 2012 Jan 31;3(3):203-6. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.